Develops immunotherapy treatments for cancer and autoimmune diseases.
Tharimmune, Inc., a clinical-stage biotechnology firm, is dedicated to advancing therapeutic candidates aimed at addressing rare diseases, inflammatory conditions, and oncological disorders. The company's robust pipeline in immuno-oncology includes promising products such as TH104, designed for the treatment of pruritogenic inflammatory conditions associated with liver diseases. Additionally, TH3215 and TH0059 are targeted at treating various solid tumors, while TH1940 focuses on inhibiting programmed cell death protein 1 (PD-1), a critical pathway in cancer immunotherapy.
Tharimmune, Inc. collaborates extensively to bolster its innovative portfolio. Notably, it has established a research collaboration and product license agreement with Minotaur Therapeutics, Inc., focusing on the development of proprietary targeted biologics. Furthermore, a partnership with Washington University in St. Louis grants Tharimmune exclusive rights to leverage technology related to multiple hybridomas and antibodies specifically targeting human HER2.
Founded as Hillstream BioPharma, Inc. and rebranded in September 2023, Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey. With a strategic focus on cutting-edge therapies and strong collaborative networks, Tharimmune is poised to make significant strides in the field of biotechnology, aiming to improve outcomes for patients grappling with challenging medical conditions worldwide.